Search - tctmd.com

Displaying 101 - 112 of 112

Sort: Relevancy | Date

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

March 09, 2013

Presentation

Sex Differences Among Patients with Type 2 Diabetes and CAD Treated with Medical Therapy With or Without Prompt Revascularization

Presenter: Jacqueline E. Tamis-Holland

March 03, 2013

Advertisement

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

Sex Differences Among Patients with Type 2 Diabetes and CAD Treated with Medical Therapy With or Without Prompt Revascularization

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content